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Abstract
Background: High incidence of thrombosis in COVID-19 patients indicates a hyper-
coagulable state. Hence, exploring the involvement of antiphospholipid antibodies 
(aPL) in these patients is of interest.
Objectives: To illustrate the incidence of criteria (lupus anticoagulant [LAC], anti-
cardiolipin [aCL] immunoglobulin G [IgG]/IgM, antibeta2-glycoprotein I antibodies 
[aβ2GPI] IgG/IgM) and noncriteria (anti-phosphatidyl serine/prothrombin [aPS/PT], 
aCL, and aβ2GPI IgA) aPL in a consecutive cohort of critically ill SARS-CoV-2 patients, 
their association with thrombosis, antibody profile and titers of aPL.
Patients/Methods: Thirty-one consecutive confirmed COVID-19 patients admitted 
to the intensive care unit were included. aPL were measured at one time point, with 
part of the aPL-positive patients retested after 1 month.
Results: Sixteen patients were single LAC-positive, two triple-positive, one double-
positive, one single aCL, and three aCL IgG and LAC positive. Seven of nine throm-
botic patients had at least one aPL. Sixteen of 22 patients without thrombosis were 
aPL positive, amongst them two triple positives. Nine of 10 retested LAC-positive 
patients were negative on a second occasion, as well as the double-positive patient. 
Seven patients were aPS/PT-positive associated to LAC. Three patients were aCL 
and aβ2GPI IgA-positive.
Conclusion: Our observations support the frequent single LAC positivity during 
(acute phase) observed in COVID-19 infection; however, not clearly related to throm-
botic complications. Triple aPL positivity and high aCL/aβ2GPI titers are rare. Repeat 
testing suggests aPL to be mostly transient. Further studies and international regis-
tration of aPL should improve understanding the role of aPL in thrombotic COVID-19 
patients.
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1  | INTRODUC TION
Since the description of the first patients with coronavirus disease 
2019 (COVID-19)-associated pneumonia, there is a growing under-
standing of the derangement of hemostasis in these patients.1-3 
Although the clinical evolution in coronavirus 2 (SARS-CoV-2) in-
fected patients with severe acute respiratory syndrome is mostly 
favorable, patients may develop acute respiratory insufficiency 
requiring admittance in the intensive care unit (ICU).4 Also, many 
patients develop a hypercoagulable state influencing the unfavora-
ble clinical outcome.3,5 Several hemostasis laboratory parameters 
are disturbed pointing to a coagulopathy.2-6 Recently reports have 
been published on antiphospholipid antibodies (aPL) in SARS-CoV-2 
patients.5,7-9 Investigators started to measure aPL in these patients 
because of the hypercoagulable state.
Indeed, antiphospholipid syndrome (APS) is an important re-
quired cause of thrombotic complications, and is defined by the 
presence of aPL.10 In the current classification criteria for APS 
lupus anticoagulant (LAC), anticardiolipin (aCL), and antibeta2-gly-
coprotein I antibodies (aβ2GPI) immunoglobulin G (IgG) or IgM are 
included as laboratory criteria, if persistently present.10,11 APS is 
a challenging diagnosis as the incidence of thrombosis is high and 
often determined by underlying factors not related to aPL resulting 
in overdiagnosis.12,13 To prevent misdiagnosis, the diagnostic workup 
for a patient with thrombosis requires besides adequate testing. a 
good collaboration between the clinician and the laboratory.14
The information on aPL in SARS-CoV-2 patients that is available 
so far is interesting, but often incomplete. Inherent to the recent 
development of the pandemic COVID-19 situation, in these patients 
only one point of measurement is obtained without confirmation 
after at least 3 months, as defined in the laboratory criteria of APS.10 
aPL can arise transiently in patients with critical illness and vari-
ous infections.15 The presence of these antibodies may rarely lead 
to thrombotic events that are difficult to differentiate from other 
causes of multifocal thrombosis in critically ill patients. To further 
investigate the role of aPL in SARS-CoV-2 patients, it is important 
to report all criteria aPL, including LAC, aCL, and aβ2GPI antibodies, 
the latter with their isotype and titer. This information is often lack-
ing in the published reports. Measuring LAC, aCL, and aβ2GPI allows 
to make antibody profiles that help in identifying patients at risk.10
Current criteria recommend increased levels of IgG and IgM 
aCL and aβ2GPI to confirm APS.10 The role of IgM aPL has been 
discussed based on a less strong association with thrombosis com-
pared with IgG.16-18 In a recent study, we illustrated that IgM was 
not an independent risk factor for thrombosis, but addition of IgM 
aCL and aβ2GPI to LAC and aCL IgG and aβ2GPI IgG increased the 
odd ratio for thrombosis, suggesting that testing for IgM might be 
useful to improve thrombotic risk stratification.18 Previously, it was 
demonstrated that the presence of aCL and aβ2GPI of the same iso-
type reinforces the clinical probability of APS.19 In the first report on 
aPL in patients with COVID-19, three patients were described with 
IgA (and IgG) aCL and aβ2GPI, without LAC positivity.7 IgA aCL and 
aβ2GPI are not included in the current classification criteria.10,11,20 In 
most cases with thrombosis, IgA aPL are usually found in association 
with IgG and/or IgM.21
The association with other aPL, such as anti-phosphatidyl ser-
ine/prothrombin (aPS/PT) merit also attention. Recent literature 
described their association with thrombosis.22,23 In the published 
series of COVID-19 patients aPS/PT is not included.
In this report, we illustrate the presence of criteria and noncri-
teria aPL, including LAC, aCL (IgG, IgM, IgA), aβ2GPI (IgG, IgM, IgA), 
and aPS/PT (IgG and IgM), in a cohort of critically ill patients with 
SARS-CoV-2 and discuss the relevance.
2  | MATERIAL S AND METHODS
2.1 | Measurement of aPL
Three-step LAC testing was carried out in a dRVVT, dilute Russell's 
viper venom time (dRVVT)- and activated partial thromboplastin 
time (APTT)-based test system according to International Society 
on Thrombosis and Haemostasis (ISTH) guidelines.24 All tests were 
carried out on a STA-R Evolution analyzer (Stago, Asnières, France) 
using Stago STA-Staclot dRVV Screen, STA-Staclot DRVV Confirm, 
PTT-LA, and Staclot LA reagents. When dRVVT confirm results ex-
ceeded the local cutoff values, screen mix/confirm mix ratios were 
applied in the confirmation step.25 Conclusions based on screening, 
mixing, and confirmatory steps were formulated for each test sys-
tem, together with a final conclusion of positivity or negativity for 
LAC. This is important to check the C-reactive protein (CRP) levels 
to avoid false positive conclusions if only the APTT system is positive 
because the APTT-based test system is prone to interferences by 
CRP.12,26 Applying the three-step procedure, unfractionated hepa-
rin (UFH) do not result in false-positive LAC, whereas enoxaparin 
cause false-positive APTT-based LAC at supra-therapeutic anti-Xa 
activity levels that exceed the heparin neutralizing capabilities of the 
reagents.27,28 In each sample, we checked the anti-Xa level to avoid 
false conclusions.
aCL and aβ2GPI IgG, IgM, and IgA were measured by ACL 
AcuStar (Werfen/Instrumentation Laboratories). A cutoff value of 
20 U/mL was applied29-31 as previously described or transferred 
from the manufacturer for IgA.20 aPS/PT IgG and IgM was measured 
by QUANTA Lite ELISA (Inova Diagnostics) with a cutoff value of 
Essentials
• COVID-19 patients develop a hypercoagulable state in-
fluencing unfavorable clinical outcome.
• Antiphospholipid antibodies (aPL) have been demon-
strated in COVID-19 patients.
• Critically ill patients shows mainly single positive lupus 
anticoagulant, mostly transient.
• The causality between aPL and thrombosis is unclear.
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30 U/mL transferred from the manufacturer.20 Solid phase assays 
were performed according to the ISTH guidelines.20
2.2 | Patient population
Thirty-one consecutive patients with confirmed COVID-19 admitted 
into the Ghent University Hospital ICU between March 11 and April 
9, 2020, were included. The study was approved by the local ethical 
committee. Patient characteristics are listed in Table 1.
All patients received prophylactic or therapeutic dose low mo-
lecular weight heparin (LMWH) (enoxaparin) or UFH (Table 1). It is 
local practice to choose UFH under a calculated creatinine clear-
ance of 30 mL/min. By this, when patients had deteriorating or im-
proving kidney function during their stay at ICU, it was possible 
that the treating physician switched from LMWH to UFH therapy 
or vice versa. UFH is also chosen during extracorporeal membrane 
oxygenation (ECMO) therapy because dose changes are more fre-
quent and thus the desired heparinization effect can be adjusted 
more quickly. Measurement of anti-Xa levels (chromogenic assays 
STA-Liquid anti-Xa, Stago) were performed routinely to ensure 
prophylactic/therapeutic levels of both LMWH and UFH heparin, 
taking the coagulopathy and interaction with acute phase proteins 
into account.32 Dose adjustments where done based on peak an-
ti-Xa concentration from the third dose of enoxaparin, in case of 
LMWH therapy. UFH therapy was titrated on steady-state levels 
of UFH every 6 hours. In highly inflammatory patients and in every 
ECMO patient, antithrombin levels were measured at the beginning 
of the LMWH or UFH heparin, but also if there were clinical con-
cerns doubting appropriate levels. Patients were routinely tested 
for D-dimers.
Thrombotic complications were confirmed by duplex ultrasound 
in case of deep venous thrombosis (DVT) or central venous catheter 
(CVC) thrombosis, the one patient with stroke underwent computed 
tomography angiography. Circuit devices were assessed routinely by 
visual inspection for the presence of clots.
3  | RESULTS
Median age in the patient population was 63 (range, 38-82) years, 
with a male/female ratio of 28/3. The median stay at the ICU was 
25 (range, 5-60) days. 26 patients received mechanical ventilation, 
five ECMO, and five renal dialysis. Anticoagulant therapy, medical 
history, and comorbidity, as well as thrombotic complications are 
shown in Table 1.
In all patients (n = 31) LAC, aCL, and aβ2GPI IgG, IgM, and IgA, 
aPS/PT IgG, and IgM were measured. Results are shown in Tables 2 
and 3.
Eight of 31 patients were negative for all criteria aPL (LAC, aCL, 
and aβ2GPI IgG and IgM), 23 patients had at least one aPL positive. 
Twenty-one of 31 patients were LAC-positive. One (patient 15) of 
21 positive LAC patients was positive only in the APTT system, but 
we are confident that this is not a false-positive result because CRP 
was elevated up to 57 mg/L and routine APTT (PTT-A, Stago) was 
more prolonged then expected according to the CRP level,26,32 and 
TA B L E  1   Patient characteristics
ICU Population (n = 31)
Age (y), median (range) 63 (38-82)
Survivors, n (%) 27 (87.1)
Male/female ratio 28/3
Medical history/comorbidity, n (%)
Cardiovascular disease 14 (45.2)
Hypercholesterolemia 3 (9.7)
Thromboembolic event 1 (3.2)
Diabetes 8 (25.8)
Obesity 4 (12.9)
Chronic renal disease 6 (19.4)
Acute renal disease 1 (3.2)
Cerebrovascular disease 1 (3.2)
Respiratory disease 2 (6.5)
Malignancies 6 (19.4)
Autoimmune disease 3 (9.7)
Agammaglobulinemia 1 (3.2)
Length of stay in the hospital, 
median (range)
33 (5-62)
Length of stay in the ICU, 
median (range)
25 (5-60)
Ventilation, n (%) 26 (83.9)
Ventilation duration (days), 
median (range)
18 (4-50)
Dialysis, n (%) 5 (16.1)
Dialysis duration (days), 
median (range)
17 (4-23)
ECMO, n (%) 5 (16.1)
ECMO duration (days), 
median (range)
17 (7-20)
Anticoagulation therapy n (%)
LMWH prophylactic 17 (54.8)
LMWH therapeutic 8 (25.8)
UFH prophylactic 2 (6.5)
UFH therapeutic 2 (6.5)
No anticoagulation therapy 2 (6.5)
Thromboembolic events during ICU stay, n (%)
CVC thrombosis 4 (12.9)
Clotting of dialysis circuit 2 (6.5)
Clotting of ECMO circuit 3 (9.7)
DVT 2 (6.5)
Stroke 1 (3.2)
Abbreviations: CVC, central venous catheter; DVT, deep vein 
thrombosis; ECMO, extracorporal membrane oxygenation; ICU, 
intensive care unit; LMWH, low molecular weight heparin; UFH, 
unfractionated heparin.
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aCL IgG was positive. One LAC-negative patient was single positive 
for aCL IgG (patient 12) and one LAC-negative patient was double 
positive for aCL IgG and aβ2GPI IgG (patient 20). Three patients had 
LAC positivity and aCL IgG (patient 3, 15, 18). Sixteen of 21 (76%) 
patients were single LAC-positive. Two patients were triple-positive 
(patients 9 and 19).
TA B L E  2   Patient test results for antiphospholipid antibodies
ID
Thrombotic 
Complications During 
ICU Stay
D-dimers aCL aβ2GPI aPS/PT LAC Repeat Testing (1 mo After First Occasion)
ng/mL
aCL IgG (U/
mL)
aCL IgM 
(U/mL)
aCL IgA 
(U/mL)
aβ2GPI IgG 
(U/mL)
aβ2GPI IgM 
(U/mL) aβ2GPI IgA (U/mL)
aPS/PT IgG 
(U/mL)
aPS/PT IgM 
(U/mL) LAC dRVVT LAC APTT
LAC final 
conclusion
LAC 
dRVVT
LAC 
APTT
LAC final 
conclusion
aCL IgG 
(U/mL)
aβ2GPI IgG 
(U/mL)
1 None 710 <3.2 <3.6 <1.4 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive − − Negative
2 Clotting dialysis 
circuita 
3790 <3.2 <3.6 2.7 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
3 CVC thrombosis 1140 22.9 8.0 3.9 <11.4 4.7 <4.0 <8.4 23.6 + + Positive − − Negative 11
4 Nonea  2170 11.4 8.1 12.4 14.8 4.0 <4.0 10.1 21.2 + + Positive
5 None 2990 9.7 <3.6 2.8 <11.4 <2.3 <4.0 <8.4 11.4 − − Negative
6 CVC thrombosisa  2380 4.8 12.8 3.8 <11.4 <2.3 <4.0 130.5 <10.8 + + Positive
7 Clotting ECMO circuit 3100 <3.2 <3.6 2.9 <11.4 2.5 <4.0 13.0 <10.8 + − Positive − − Negative
8 None 2010 10.9 <3.6 9.3 <11.4 <2.3 9.8 11.4 <10.8 − − Negative
9 None 300 6.1 467.8 3.0 28.8 212.8 <4.0 <8.4 15.5 + − Positive
10 None 1160 12.0 <3.6 2.2 <11.4 <2.3 <4.0 13.5 <10.8 − − Negative
11 None 2690 4.4 <3.6 3.0 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
12 None 2080 28.0 4.4 3.0 <11.4 3.8 <4.0 <8.4 11.4 − − Negative
13 None 2850 <3.2 <3.6 <1.4 <11.4 <2.3 <4.0 <8.4 32.3 + − Positive
14 None 4500 17.1 3.6 6.7 <11.4 <2.3 <4.0 10.81 32.7 + − Positive
15 CVC thrombosis 2000 36.2 <3.6 7.1 <11.4 2.7 <4.0 <8.4 18.9 − + Positive
16 clotting ECMO circuit 2940 11.6 <3.6 3.9 <11.4 4.8 <4.0 <8.4 <10.8 − − Negative
17 None 2600 4.6 13.3 74.5 <11.4 3.4 90.2 27.3 26.9 + − Positive − − Negative
18 CVC thrombosis, DVT, 
stroke
5790 32.9 <3.6 3.2 <11.4 3.4 <4.0 <8.4 <10.8 + − Positive − − Negative 7.4
19 None 380 27.3 <3.6 91.2 129.4 <2.3 127.1 72.1 12.1 + + Positive + + Positive 13.8 49.1
20 None 1450 22.4 8.6 3.7 33.0 4.1 <4.0 <8.4 <10.8 − − Negative 2.6 19.9
21 None 2150 4.4 6.2 13.6 <11.4 13.3 16.4 <8.4 13.4 + + Positive − − Negative
22 None 2310 3.2 3.6 2.5 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
23 None 380 3.2 3.6 1.6 <11.4 2.8 <4.0 <8.4 <10.8 + + Positive
24 DVT 1100 16.8 7.0 208.2 <11.4 2.9 416.5 <8.4 60.1 + − Positive
25 None 1910 <3.2 <3.6 2.1 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive − − Negative
26 None 460 <3.2 <3.6 2.5 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive − − Negative
27 None 2150 <3.2 5.5 3.3 <11.4 5.8 <4.0 <8.4 38.8 + + Positive
28 None 570 <3.2 <3.6 <1.4 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
ID
Thrombotic 
complications during 
ICU stay
D-Dimers Anticardiolipin antibodies Antibeta2-glycoprotein I antibodies Anti-PS/PT antibodies Lupus anticoagulant Repeat testing (1 mo after first occasion)
ng/mL
aCL IgG 
(U/mL)
aCL IgM 
(U/mL)
aCL IgA 
(U/mL)
aβ2GPI IgG 
(U/mL) aβ2GPI IgM (U/mL) aβ2GPI IgA (U/mL)
aPS/PT IgG 
(U/mL)
aPS/PT IgM 
(U/mL) LAC dRVVT LAC APTT
LAC final 
conclusion
LAC 
dRVVT
LAC 
APTT
LAC final 
conclusion
aCL IgG 
(U/mL)
aβ2GPI IgG 
(U/mL)
29 Clotting ECMO and 
Dialysis circuit
>20 000 18.4 <3.6 4.1 <11.4 <2.3 <4.0 14.7 <10.8 + − Positive − − Negative
30 Nonea  3160 <3.2 <3.6 3.4 <11.4 <2.3 <4.0 285.9 <10.8 + + Positive
31 None 450 3.2 3.6 <1.4 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive
Note: All positive results are written in bold type.
−, negative; +, positive; aCL, anticardiolipin antibodies; aPS/PT, anti-prothrombin/phosphatidyl serine antibodies; APTT, activate partial  
thromboplastin time; aβ2GPI, antibeta2-glycoprotein I antibodies; CVC, central venous catheter; dRVVT, dilute Russell's viper venom time; DVT,  
deep vein thrombosis; ECMO, extracorporal membrane oxygenation; ICU, intensive care unit; ID, patient identification; LAC, lupus anticoagulant.
aPatient died during stay in ICU. 
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Seven of nine patients with thrombotic complications had at 
least one criterion aPL-positive, and four with single LAC posi-
tivity. Sixteen of 22 patients without thrombotic complications 
showed positivity for at least one criterion aPL, 13 with single 
LAC positivity. The two triple-positive patients had no thrombotic 
complications.
TA B L E  2   Patient test results for antiphospholipid antibodies
ID
Thrombotic 
Complications During 
ICU Stay
D-dimers aCL aβ2GPI aPS/PT LAC Repeat Testing (1 mo After First Occasion)
ng/mL
aCL IgG (U/
mL)
aCL IgM 
(U/mL)
aCL IgA 
(U/mL)
aβ2GPI IgG 
(U/mL)
aβ2GPI IgM 
(U/mL) aβ2GPI IgA (U/mL)
aPS/PT IgG 
(U/mL)
aPS/PT IgM 
(U/mL) LAC dRVVT LAC APTT
LAC final 
conclusion
LAC 
dRVVT
LAC 
APTT
LAC final 
conclusion
aCL IgG 
(U/mL)
aβ2GPI IgG 
(U/mL)
1 None 710 <3.2 <3.6 <1.4 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive − − Negative
2 Clotting dialysis 
circuita 
3790 <3.2 <3.6 2.7 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
3 CVC thrombosis 1140 22.9 8.0 3.9 <11.4 4.7 <4.0 <8.4 23.6 + + Positive − − Negative 11
4 Nonea  2170 11.4 8.1 12.4 14.8 4.0 <4.0 10.1 21.2 + + Positive
5 None 2990 9.7 <3.6 2.8 <11.4 <2.3 <4.0 <8.4 11.4 − − Negative
6 CVC thrombosisa  2380 4.8 12.8 3.8 <11.4 <2.3 <4.0 130.5 <10.8 + + Positive
7 Clotting ECMO circuit 3100 <3.2 <3.6 2.9 <11.4 2.5 <4.0 13.0 <10.8 + − Positive − − Negative
8 None 2010 10.9 <3.6 9.3 <11.4 <2.3 9.8 11.4 <10.8 − − Negative
9 None 300 6.1 467.8 3.0 28.8 212.8 <4.0 <8.4 15.5 + − Positive
10 None 1160 12.0 <3.6 2.2 <11.4 <2.3 <4.0 13.5 <10.8 − − Negative
11 None 2690 4.4 <3.6 3.0 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
12 None 2080 28.0 4.4 3.0 <11.4 3.8 <4.0 <8.4 11.4 − − Negative
13 None 2850 <3.2 <3.6 <1.4 <11.4 <2.3 <4.0 <8.4 32.3 + − Positive
14 None 4500 17.1 3.6 6.7 <11.4 <2.3 <4.0 10.81 32.7 + − Positive
15 CVC thrombosis 2000 36.2 <3.6 7.1 <11.4 2.7 <4.0 <8.4 18.9 − + Positive
16 clotting ECMO circuit 2940 11.6 <3.6 3.9 <11.4 4.8 <4.0 <8.4 <10.8 − − Negative
17 None 2600 4.6 13.3 74.5 <11.4 3.4 90.2 27.3 26.9 + − Positive − − Negative
18 CVC thrombosis, DVT, 
stroke
5790 32.9 <3.6 3.2 <11.4 3.4 <4.0 <8.4 <10.8 + − Positive − − Negative 7.4
19 None 380 27.3 <3.6 91.2 129.4 <2.3 127.1 72.1 12.1 + + Positive + + Positive 13.8 49.1
20 None 1450 22.4 8.6 3.7 33.0 4.1 <4.0 <8.4 <10.8 − − Negative 2.6 19.9
21 None 2150 4.4 6.2 13.6 <11.4 13.3 16.4 <8.4 13.4 + + Positive − − Negative
22 None 2310 3.2 3.6 2.5 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
23 None 380 3.2 3.6 1.6 <11.4 2.8 <4.0 <8.4 <10.8 + + Positive
24 DVT 1100 16.8 7.0 208.2 <11.4 2.9 416.5 <8.4 60.1 + − Positive
25 None 1910 <3.2 <3.6 2.1 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive − − Negative
26 None 460 <3.2 <3.6 2.5 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive − − Negative
27 None 2150 <3.2 5.5 3.3 <11.4 5.8 <4.0 <8.4 38.8 + + Positive
28 None 570 <3.2 <3.6 <1.4 <11.4 <2.3 <4.0 <8.4 <10.8 − − Negative
ID
Thrombotic 
complications during 
ICU stay
D-Dimers Anticardiolipin antibodies Antibeta2-glycoprotein I antibodies Anti-PS/PT antibodies Lupus anticoagulant Repeat testing (1 mo after first occasion)
ng/mL
aCL IgG 
(U/mL)
aCL IgM 
(U/mL)
aCL IgA 
(U/mL)
aβ2GPI IgG 
(U/mL) aβ2GPI IgM (U/mL) aβ2GPI IgA (U/mL)
aPS/PT IgG 
(U/mL)
aPS/PT IgM 
(U/mL) LAC dRVVT LAC APTT
LAC final 
conclusion
LAC 
dRVVT
LAC 
APTT
LAC final 
conclusion
aCL IgG 
(U/mL)
aβ2GPI IgG 
(U/mL)
29 Clotting ECMO and 
Dialysis circuit
>20 000 18.4 <3.6 4.1 <11.4 <2.3 <4.0 14.7 <10.8 + − Positive − − Negative
30 Nonea  3160 <3.2 <3.6 3.4 <11.4 <2.3 <4.0 285.9 <10.8 + + Positive
31 None 450 3.2 3.6 <1.4 <11.4 <2.3 <4.0 <8.4 <10.8 + + Positive
Note: All positive results are written in bold type.
−, negative; +, positive; aCL, anticardiolipin antibodies; aPS/PT, anti-prothrombin/phosphatidyl serine antibodies; APTT, activate partial  
thromboplastin time; aβ2GPI, antibeta2-glycoprotein I antibodies; CVC, central venous catheter; dRVVT, dilute Russell's viper venom time; DVT,  
deep vein thrombosis; ECMO, extracorporal membrane oxygenation; ICU, intensive care unit; ID, patient identification; LAC, lupus anticoagulant.
aPatient died during stay in ICU. 
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Repeat testing of positive aPL results 1 month after the first oc-
casion could be performed in part (11/31) of the patient population. 
Samples after 1 month were not available from all patients.
LAC was repeated in 10 of 21 patients that were LAC-positive 
during the first period of testing. Nine of ten patients were LAC-
negative on the second occasion. One (patient 19) of the two tri-
ple-positive patients was included in the repeat testing series and 
showed persistent LAC positivity after 1 month. However, the aCL 
IgG originally positive around the cutoff value was negative by repeat 
testing. In this patient, aβ2GPI IgG persisted positive by repeat test-
ing, albeit with a lower titer. Repeat testing of borderline positive aCL 
IgG and low positive aβ2GPI IgG (patient 20) was negative on the sec-
ond testing. Seven patients were single LAC-positive on the first occa-
sion, two patients (patients 3 and 18) were combined positive for LAC 
TA B L E  3   Patient test results for lupus anticoagulant
Patient ID
Results LAC dRVVT Results LAC APTT
LAC Final 
Conclusion
Screen 
N ratio
Screen Mix 
N ratio
Screen/Confirm 
N ratio Conclusion
Screen 
N ratio
Screen Mix 
N ratio
Delta 
(s)a  Conclusion
Cutoff 1.39 1.10 1.10 1.33 1.12 8.0
1 1.86 1.42 1.27 + 1.91 1.59 24.7 + Positive
2 1.31 − 1.86 1.42 1.5 − Negative
3 1.51 1.21 1.14 + 1.92 1.42 19.1 + Positive
4 2.63 1.60 1.61 + 1.53 1.13 11.6 + Positive
5 1.25 − 0.95 − Negative
6 1.92 1.29 1.30 + 3.49 2.28 21.3 + Positive
7 2.49 1.64 1.59 + 1.10 − Positive
8 1.07 − 1.16 − Negative
9 1.44 1.21 1.10b  + 1.41 1.23 7.4 − Positive
10 0.94 − 1.00 − Negative
11 1.29 − 1.08 − Negative
12 1.36 − 1.03 − Negative
13 1.65 1.24 1.23 + 0.98 − Positive
14 1.94 1.43 1.42 + 1.13 − Positive
15 1.39 − 1.45 1.17 8.9 + Positive
16 1.27 − 0.87 − Negative
17 1.55 1.29 1.26 + 1.22 − Positive
18 1.63 1.37 1.32 + 1.04 − Positive
19 3.15 1.84 1.71 + 2.08 1.41 23.7 + Positive
20 1.35 − 0.95 − Negative
21 1.71 1.41 1.28 + 1.72 1.36 18.6 + Positive
22 1.21 − 1.09 − Negative
23 1.78 1.31 1.16 + 1.73 1.38 22.9 + Positive
24 1.42 1.19 1.10b  + 1.23 − Positive
25 1.96 1.43 1.35 + 1.40 1.25 25.2 + Positive
26 1.68 1.28 1.19 + 1.69 1.42 18.5 + Positive
27 1.56 1.32 1.14 + 1.38 1.29 14.9 + Positive
28 1.29 − 0.97 − Negative
29 1.46 1.21 1.17 + 4.04 2.13 6.1 − Positive
30 1.87 1.73 1.71 + 2.45 2.07 49.6 + Positive
31 2.38 1.27 1.16 + 3.20 1.17 30.0 + Positive
All positive results are written in bold type (in-house calculated cutoff values on 120 normals).
Abbreviations: −, negative; +, positive; APTT, activate partial thromboplastin time; dRVVT, dilute Russell's viper venom time; ID, patient 
identification; LAC, lupus anticoagulant; N ratio, normalized ratio; s, seconds.
aConfirmatory step for APTT (Staclot LA) is expressed as a difference in clotting time between two APTTs with and without hexagonal phase 
phosphatidyl ethanolamine. 
bdRVVT Screen Mix/Confirm Mix N ratio > cutoff (0.92). 
     |  2197DEVREESE Et al.
and aCL IgG (borderline positive). These patients also tested negative 
for aCL IgG by repeat testing. Four of the nine patients with negative 
LAC during repeat testing showed thrombotic complications.
The aPS/PT IgG were positive in three patients (patients 6, 19, 
30); one patient with single LAC positivity and thrombosis, one 
triple-positive patient, and one single LAC-positive patient, both 
without thrombotic complications, respectively. aPS/PT IgM were 
positive in four patients (patients 13, 14, 24, 30), three with single 
LAC positivity and no thrombotic complications, and one with single 
LAC positivity and DVT, respectively.
aCL IgA and aβ2GPI IgA was combined positive in three patients 
(patients 17, 19, 24), all associated with LAC. One patient had DVT.
All patients had elevated D-dimers (Table 2).
4  | DISCUSSION
The incidence of both arterial and venous thromboembolism is high 
in COVID-19 patients, and laboratory markers may help in raising 
suspicion of underlying thrombotic problems.33-36 Changes in co-
agulation parameters detecting the procoagulant state in COVID-19 
patients associated with poor clinical outcome were reported.3-6 
Simple, and for most institutions available, laboratory markers 
such as platelet count, D-dimers, prothrombin time, and fibrinogen 
seemed relevant for laboratory monitoring for COVID-19 related 
coagulopathy in addition to clinical assessment.36,37 The hemostatic 
changes observed in COVID-19 are previously also been shown in 
association with other coronaviruses,38 and some viruses are known 
to activate the coagulation system.39
Clinical experience learns that the hypercoagulable state in 
critically ill COVID-19 patients comprise diverse types of throm-
boembolic complications that need adequate anticoagulant ther-
apy.5,36,40-42 Triggered by the hypercoagulable state of these patients 
and the high incidence of thrombosis, involvement of aPL has been 
suggested and reports have been published on measurement of aPL 
in COVID-19 patients.5,7-9,42
Zhang et al described three patients with multiple cerebral in-
farctions and presence of aCL IgA and aβ2GPI IgG and IgA positivity, 
measured on one occasion, without details on the titers provided. 
No LAC was detected in these patients.7 The three patients fulfilled 
the clinical criteria for APS,11 but had also other comorbidities asso-
ciated with thrombosis.7
Harzallah et al tested 56 COVID-19 patients for aPL, and found 
45% LAC positive, and 10% either aCL or aβ2GPI IgG or IgM positive, 
of which three were associated with LAC. Titers of aCL or aβ2GPI 
were not reported, and no details were provided on whether LAC 
was positive in the APTT and/or dRVVT test system and associated 
thrombosis was not mentioned.9
Bowles et al described 35 patients in detail, and detected 
91% of 35 patients positive for LAC in a workout for prolonged 
APTT.8 Six of 35 patients (18%) were positive in the APTT system 
only. aCL or aβ2GPI were not measured and only two patients had 
thrombosis.8
Helms et al tested for LAC in 57 patients with a thrombotic 
event during their stay at the ICU or when a coagulation disorder 
was suspected based on prolonged APTT.5 LAC testing did not in-
clude a confirmatory step for the APTT system, and LAC was con-
sidered positive based on the dRVVT test system results only. They 
observed 88% positives for LAC.5 aCL and aβ2GPI were not tested, 
but one patient seemed to have aCL IgM (48 MLP [IgM phospholipid 
units]) positive before the COVID-19 infection. The number of LAC-
positive patients with confirmed thrombosis is not reported. In the 
overall population, 64 of 150 patients (43%) had thrombosis.5
In two of the four published studies, COVID-19 patients were 
not tested for aCL and aβ2GPI.5,8 If not all criteria aPL are mea-
sured, no antibody profiles could be done that proved to be useful 
because combining the aPL may improve risk assessment.10,11,43-45 
Combined positivity for LAC, aCL, and aβ2GPI antibodies (ie, triple 
positivity) has been shown to be associated with a high risk of both 
a first thrombotic event and recurrence.46-48 Double-positive (LAC-
negative) patients are at lower risk than triple-positive patients, and 
single-positive patients are less likely to develop APS-related clinical 
symptoms.10,44 Isolated positivity for LAC is often observed in ab-
sence of clinical symptoms, in elderly patients, on a first occasion 
not confirmed after 12 weeks.44,49,50 An isolated LAC is an inde-
pendent risk factor for myocardial infarction and ischemic stroke, 
however.51,52
The aPL antibody profiles demonstrated in COVID-19 patients 
have a low-risk profile for thrombosis. Studies that included aCL 
and aβ2GPI showed mainly single LAC-positive patients.9 In the 
study of Zhang et al,7 considering the criteria aPL,10 the three pa-
tients described show single positivity for aβ2GPI IgG. In our study 
population, 23% (7/31) of patients had aCL and/or aβ2GPI, slightly 
higher compared with the study of Harzallah et al.9 In previously 
reported cohorts,7,9 aCL or aβ2GPI titers were not reported and 
cannot be valued against the high titers that are required accord-
ing to the guidelines.11,20 In our cohort, the titers of aCL IgG ranged 
from 22.4 to 36.2 U/mL, although our cutoff value corresponds to 
the 99th percentile20 experience shows that these titers are “low” 
positive for the solid phase test system we used.29,30 Moreover, 
values around the cutoff value (three of the five positive samples) 
should be interpreted with care.20 Only triple-positive patients 
demonstrated higher titers (patients 9 and 19). All patients with 
high titers aCL or aβ2GPI did not have thrombotic complications 
so far.
As far as interpretable and based on available results in previ-
ous studies,5,7-9 in none of the patients was triple positivity demon-
strated. In our patient cohort, only two patients were triple positive, 
of whom none showed thrombotic complications. Although the in-
cidence of aPL in our cohort was high with 74% of patients positive 
for at least one criterion aPL, the majority of patients showed a low-
risk profile: 16 single LAC positives, one sample with single aCL, one 
sample with double positivity, and three samples with LAC and aCL 
positivity.
In previous studies,5,7-9 the association of aPL and thrombosis is 
strongly highlighted, but it is unclear whether all these patients were 
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prophylactically anticoagulated. In our cohort of ICU patients, who 
tested all positive for D-dimers, we observed no strong association 
of aPL and thrombotic complications. Among the described throm-
botic complications in COVID-19 patients (clotting of CVC, clot-
ting of dialysis filters, stroke, DVT, and ischemic limbs), we mainly 
observed CVC and circuit device clotting; one of the nine patients 
with thrombotic complications showed stroke and another patient 
showed DVT.40,53 There was no relationship between D-dimers 
and aPL, thrombosis, or outcome. In patients with thrombosis, 67% 
showed positivity for aPL; in the patients without thrombosis, 72% 
tested positive for at least one aPL. During ECMO treatment, all five 
patients received UFH. Importantly, in our cohort, the majority of 
patients were treated with heparins to prevent thrombotic compli-
cations. This supports that patients should be anticoagulated be-
cause coagulopathy is one of the key features associated with poor 
outcomes.33,36
Regarding the isotype, in our study, one triple-positive patient 
(patient 9) was positive for aPL IgM. In the patient population de-
scribed by Harzallah et al, maximally 10% were IgM positive and 
all aCL/aβ2GPI-positive patients were associated with LAC. In our 
study population, we observed two patients with aCL/aβ2GPI not 
associated to LAC, all of whom were IgG positive. This is in line with 
what we illustrated in a recent multicenter study: that isolated posi-
tivity of IgM was rare in thrombotic APS and that it was not an inde-
pendent risk factor for thrombosis.18
Despite aCL and aβ2GPI IgA not being included in the current clas-
sification criteria,10 we tested for IgA. Zhang et al found all three pa-
tients (with cerebral infarctions) positive for both aCL and aβ2GPI IgA 
without LAC positivity.7 We observed three patients positive for both 
aCL and aβ2GPI IgA (high titers), associated with LAC, of whom one 
patient had DVT. In two of the three patients, aCL/aβ2GPI IgG and 
IgM were negative, which is relatively high (2/31, 6%) compared with 
an APS setting where isolated IgA positivity is rare in patients with 
clinical manifestations of APS.31 In most cases with major APS man-
ifestations (ie, thrombosis), IgA aPL are usually found in association 
with IgG and/or IgM.21 The number of patients positive for IgA aPL 
(n = 3) compared with IgG (n = 8) and IgM (n = 2), is comparably low.
In this COVID-19 cohort, the role of IgA is unclear, without 
added value on top of the current classification criteria, equally as 
previously illustrated in APS.10,21,30
Amongst noncriteria aPL, aPS/PT is a group of aPL that merit at-
tention, based on recent literature describing their association with 
thrombosis.22,23 aPS/PT antibodies are strongly associated with LAC 
and frequently present in APS patients.49,54 In our COVID-19 cohort, 
we observed aPS/PT IgM positivity in 25% (4/16; patients 13, 14, 24, 
27) of the single LAC positives, of which one patient suffered from 
DVT. Three patients were positive for aPS/PT IgG (patients 6, 19, 
30), two with single LAC positivity, of which one had CVC throm-
bosis and two (one with triple positivity) had no thromboembolic 
complications. The association of LAC and aPS/PT seems lower than 
expected based on results in APS patients. Today, aPL against only 
two plasma proteins, β2GPI and prothrombin, are found frequently 
enough in APS patients to attribute them a pathophysiological role. 
In the absence of aβ2GPI, LAC positivity signifies a β2GPI-indepen-
dent LAC whose association with thrombosis is uncertain.44 The 
single LAC positivity frequently observed in COVID-19 patients 
might be explained by LAC activity through other cofactors. We can 
speculate that in these single LAC-positive patients (hence aβ2GPI 
negativity, and also aPS/PT negativity), aPL binding through other 
cofactors, such as complement C4 or factor H, may be responsible 
for the LAC positivity. Additionally, the role of complement activa-
tion and cytokine storm has been described in COVID-19 and may 
play a role in the microvascular injury and organ dysfunction.10,42,55
In the published studies, there is no information on LAC (or other 
aPL) positivity before COVID-19 infection. In the context of APS, 
previous studies illustrated that in asymptomatic carriers the num-
ber of events was much lower in double and single LAC positives 
compared with triple positives.48,56 Double-positive (LAC-negative) 
patients were at lower risk than triple-positive patients, and sin-
gle-positive patients are less likely to develop APS-related clinical 
symptoms.10,44 If we assume that all patients testing positive for LAC 
during COVID-19 infection were asymptomatic carriers, we should 
also assume they are less expected to develop aPL-related throm-
bosis. Also, in our study, we did not test for aPL in the majority of 
patients before COVID-19 infection. At COVID-19 infection, one pa-
tient was diagnosed as asymptomatic carrier with persistent positive 
single LAC and did not develop thrombosis during infection but had 
severe comorbidity and died during his stay at the ICU. The two tri-
ple-positive carriers in our cohort did not develop thrombosis at the 
time of this writing.
All aPL analyses were performed during the acute phase, which 
is discouraged in the guidelines because of possible interferences 
with the test result.24 Single LAC positivity is a common find-
ing in all COVID-19-related studies measuring aPL. Isolated LAC 
may also be the consequence of the complicated methodology of 
phospholipid-dependent coagulation tests that are prone to inter-
ferences.12,24,26 In some of the published reports, there is concern 
about the methodology because most of these critically ill patients 
have raised levels of CRP, that may results in false-positive LAC26 
In some publications, we can rule out this reason for false positiv-
ity,5,8 but in others we cannot.9 One of the major drawbacks of LAC 
testing is also the interference of anticoagulant therapy.28 COVID-
19 patients are treated with heparins,36 but interference of hepa-
rins is probably not a real issue here because reagents dedicated for 
LAC testing contain heparin neutralizers, and LAC analysis is reli-
able if antiXa levels of heparins are within the therapeutic range.28 
Although we also tested during the acute phase in our observational 
study, we are confident of not having false-positive LAC because we 
checked for CRP and antiXa levels, and nevertheless observed 52% 
(16/31) single LAC-positive patients.
A major drawback of all COVID-19-related studies on aPL is the 
lack of confirmed positivity of aPL after 3 months.10 Positive results 
of LAC, aCL, or aβ2GPI need to be confirmed on a second occasion 
after 12 weeks to confirm persistent positivity.10 We had the oc-
casion to retest some patients at a second time point, at 1 month 
distance from the first testing period. All but one patient retested for 
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LAC became negative, for aCL IgG all retested positive patients were 
negative. It is noteworthy that the retested triple-positive patient 
turned into negative for one aPL (aCL IgG) after 1 month. Transient 
antibodies have been described in infectious diseases or drugs and 
are thought of not being of clinical significance; therefore, retest-
ing was originally meant to avoid overdiagnosis of APS patients that 
were not persistently positive.10,11 Some studies demonstrated that 
aPL, with properties similar to those found in patients with APS, can 
be induced by immunization with β2GPI-like PL-binding viral and 
bacterial products. However, it is not certain that these aPL antibod-
ies are pathogenic, and the clinical significance remains unknown. 
Infection-induced aPL is transient in some patients, and in some 
individuals they persist and can be associated with thrombosis.15,57 
Infectious agents are triggers for the formation of aPL and molec-
ular mimicry between structures of bacteria or viruses and β2G-
PI-derived amino acid sequences are thought to contribute to the 
formation of autoantibodies.58 But only with the appropriate genetic 
background or following secondary triggers do these antibodies be-
come pathogenic. Triggers probably push the hemostatic balance in 
favor of thrombosis and might include environmental factors such 
as infection.59
Limitations of our study are the small patient population and the 
limited number of patients that were retested on a second occasion 
on distance from the first testing.
In summary, the observations in our study support the finding of 
frequent single LAC positivity in the acute phase of the COVID-19 
infection, but not clearly related to thrombotic complications. Albeit 
our study population is small, triple-positive patients are rare, and ti-
ters of aCL and aβ2GPI are high only in the minority of patients. LAC 
positivity does not correspond with aPS/PT as we observe in APS. 
Repeat testing in a limited number of patients suggests that most of 
the aPL are transient.
We can conclude that it is clear that alterations in the hemostatic 
balance in COVID-19 patients is strongly disturbed and contribute to 
a high prothrombotic status, justifying the use of anticoagulant ther-
apy. The hypercoagulability observed in COVID-19 patients is prob-
ably multifactorial, and not clarified today. Inflammation is closely 
associated to thrombosis and dysregulation in the coexistence and 
interplay of hemostatic and inflammatory mediators can result in 
clinical manifestations of disease, including thrombosis.60 On top of 
all the interest in this new virus, the association between viral and 
bacterial infections with high inflammatory state and the incidence 
of thromboembolic events is not a new finding.61
Today, it is premature to conclude there is a contribution of aPL 
to thrombosis in these patients. Further studies are needed to fur-
ther unravel the role of aPL in COVID-19 patients and the relation 
with thrombosis. The presence of aPL should be interpreted with 
appropriate reservations and we should be conscious that preana-
lytical and analytical variables can affect test results, especially for 
LAC. Large well-designed clinical studies are required before clear 
conclusions can be made on routine testing of aPL in COVID-19 
patients. Also, we have to follow-up on the first measurements we 
now have available, to evaluate the persistence of the positive aPL 
in these patients. An international registry of aPL measurement and 
follow-up should be very helpful in understanding the role of aPL in 
thrombotic complications in COVID-19 patients.
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